|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
Phase 1b, multi-center, single-blinded, randomized, placebo-controlled study, evaluating safety, tolerability and efficacy of different doses and regimens of Allocetra-OTS, in up to 50 adult patients with critical COVID-19.
Description: Number and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).Measure: Safety - Adverse Events Time: 28 days
Description: Change in PaO2 or SO2/FiO2 RatioMeasure: Efficacy - PaO2 or SO2/FiO2 Ratio Time: 28 days
Description: Change from baseline in Sequential Organ Failure Assessment (SOFA) scoreMeasure: Efficacy - SOFA score Time: 7 days
Description: All-cause mortalityMeasure: Efficacy - mortality Time: 28 days
Description: Oxygen free days, vasopressors free days, cumulative days in ICU or IMUMeasure: Efficacy - organ function / support measurements Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports